Characteristics of individuals with Staphylococcus aureus bacteraemia with and without HIV-1 infection
| All n=245 | HIV-1 infected n=82 | HIV-1 uninfected n=163 | p Value | |
|---|---|---|---|---|
| Age, years (range) | 40 (18–86) | 37 (18–79) | 41 (19–86) | 0.03 |
| Male (%) | 145 (59.2) | 49 (59.8) | 96 (58.9) | – |
| Nationality (%) | ||||
| Danish/European | 222 (90.6) | 73 (89) | 149 (91.4) | |
| Non-European | 23 (9.4) | 9 (11) | 14 (8.6) | 0.64 |
| MRSA (%) | 5 (2.0) | 3 (3.7) | 2 (1.2) | 0.33 |
| Origin (%) | ||||
| Community | 156 (63.7) | 62 (75.6) | 94 (57.7) | |
| Hospital | 69 (28.2) | 15 (19.5) | 53 (32.5) | |
| Healthcare associated | 20 (8.1) | 4 (4.9) | 16 (9.8) | 0.02 |
| IDU (%) | ||||
| No | 139 (56.7) | 39 (47.6) | 100 (61.3) | |
| Current | 99 (40.4) | 42 (51.2) | 57 (35.0) | |
| Former | 7 (2.9) | 1 (1.2) | 6 (3.7) | 0.04 |
| Entry (%) | ||||
| Surgical | 9 (3.7) | 2 (2.4) | 7 (4.3) | |
| Skin infection | 60 (24.5) | 17 (20.7) | 43 (26.4) | |
| Intravenous line | 29 (11.8) | 10 (12.2) | 19 (11.7) | |
| Active IDU | 77 (31.4) | 36 (43.9) | 41 (25.2) | |
| Other | 17 (6.9) | 2 (2.4) | 15 (9.2) | |
| Unknown | 53 (21.6) | 15 (18.3) | 38 (23.2) | 0.04 |
| Secondary manifestation (%) | ||||
| None | 163 (66.8) | 54 (66.7) | 109 (66.9) | |
| Endocarditis | 39 (16.0) | 12 (14.8) | 27 (16.6) | |
| Osteomyelitis | 13 (5.3) | 8 (9.9) | 5 (3.1) | |
| Arthritis | 8 (3.3) | 1 (1.2) | 7 (4.3) | |
| Meningitis | 1 (0.4) | 1 (1.2) | 0 | |
| Other | 20 (8.1) | 5 (6.2) | 15 (9.2) | 0.11 |
| Devices (%) | ||||
| None | 133 (54.2) | 57 (69.5) | 76 (46.6) | |
| Peripheral venous catheter | 46 (18.8) | 8 (9.8) | 38 (23.3) | |
| Central venous catheter | 58 (23.7) | 16 (19.5) | 42 (25.8) | |
| Other | 8 (3.3) | 1 (1.2) | 7 (4.3) | 0.004 |
| Comorbidity (%) | ||||
| 0 | 71 (29.0) | 34 (41.5) | 37 (22.7) | |
| 1 | 120 (49.0) | 43 (52.4) | 77 (47.2) | |
| >1 | 54 (22.0) | 5 (6.1) | 49 (30.1) | 0.0001 |
| Pitt score (%) | ||||
| 0–3 | 216 (89.3) | 75 (92.6) | 141 (87.6) | |
| >3 | 26 (10.7) | 6 (7.4) | 20 (12.4) | 0.28 |
| Period (%) | ||||
| 1995–1997 (pre-ART) | 60 (24.5) | 22 (26.8) | 38 (23.3) | |
| 1997–1999 (early-ART) | 51 (20.8) | 28 (34.1) | 23 (14.1) | |
| 2000 (late-ART) | 134 (54.7) | 32 (39) | 102 (62.6) | 0.0001 |
ART, antiretroviral therapy; IDU, injection drug use; MRSA, methicillin-resistant Staphylococcus aureus.